These experiments demonstrate that SH-BC-893 reduces nuclear levels of prostate cancer drivers MYC and the AR by triggering PP2A-dependent proteasomal degradation and blocking KPNB1-mediated nuclear import in parallel, redundancy that could limit the development of drug resistance. Here, AR is linked to prostate cancer.